| [1] |
张志强, 马怡, 郑爽, 等. 实体肿瘤治疗效果评价标准的研究进展[J]. 中国临床实用医学, 2019, 10(2): 71-73. DOI: 10.3760/cma.j.issn.1673-8799.2019.02.020.
|
| [2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [3] |
Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J]. Semin Oncol, 2020, 47(5): 259-269. DOI: 10.1053/j.seminoncol.2020.07.008.
pmid: 32896428
|
| [4] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792. DOI: 10.1056/NEJM200103153441101.
|
| [5] |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274. DOI: 10.1200/JCO.2005.04.173.
|
| [6] |
Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data[J]. Ann Oncol, 2001, 12 Suppl 1: S57-S62.
|
| [7] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-3752. DOI: 10.1200/JCO.2014.55.5730.
pmid: 25332249
|
| [8] |
Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the North central cancer treatment group N9831 clinical trials[J]. J Clin Oncol, 2010, 28(21): 3416-3421. DOI: 10.1200/JCO.2009.23.6950.
pmid: 20530275
|
| [9] |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(10075): 1195-1205. DOI: 10.1016/S0140-6736(16)32616-2.
pmid: 28215665
|
| [10] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273-1283. DOI: 10.1056/NEJMoa0910383.
|
| [11] |
Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol, 2009, 27(34): 5685-5692. DOI: 10.1200/JCO.2008.21.4577.
pmid: 19884557
|
| [12] |
Valero V, Forbes J, Pegram MD, et al. Multicenter phase Ⅲ randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer(BCIRG 007 study): two highly active therapeutic regimens[J]. J Clin Oncol, 2011, 29(2): 149-156. DOI: 10.1200/JCO.2010.28.6450.
|
| [13] |
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530. DOI: 10.1016/S1470-2045(19)30863-0.
pmid: 32171426
|
| [14] |
韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J]. 中华普通外科学文献(电子版), 2021, 15(6): 453-458. DOI: 10.3877/cma.j.issn.1674-0793.2021.06.013.
|
| [15] |
边莉, 徐兵河, 邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30): 2351-2357. DOI: 10.3760/cma.j.cn112137-20200116-00105.
|
| [16] |
Wang T, Zhang P, Di LJ, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study[J]. Transl Breast Cancer Res, 2022, 3: 15. DOI: 10.21037/tbcr-21-42.
pmid: 38751509
|
| [17] |
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792. DOI: 10.1200/JCO.2005.04.1764.
|
| [18] |
Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983. DOI: 10.1200/JCO.2008.21.6531.
pmid: 20038734
|
| [19] |
Xu BH, Li W, Zhang QY, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase Ⅲ, randomized, double-blind, placebo-controlled study[J]. Breast Cancer Res Treat, 2023, 197(3): 503-513. DOI: 10.1007/s10549-022-06775-1.
|
| [20] |
王晓闻, 刘培培, 吕锋华, 等. 抗HER2人源化单克隆抗体药物关键质量属性评价[J]. 中国药学杂志, 2015, 50(12): 1054-1061. DOI: 10.11669/cpj.2015.12.014.
|
